Progress in chitosan-based vaccine delivery systems

Journal of Drug Delivery Science and Technology

Volumn 20, Issue 1, 2010, Pages 53-61

  Esmaeili, F ^a,b   Heuking, S ^a,b   Junginger, H E ^c   Borchard, G ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Centre Interuniversitaire de Recherche et d'Enseignement   (France)

^c NARESUAN UNIVERSITY   (Thailand)

Author keywords

Chitosan; Chitosan derivative; Mucosal immunization; Vaccine carrier system

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; CHITOSAN; CHITOSAN DERIVATIVE; CHOLERA VACCINE; DERMONECROTOXIN VACCINE; DIPHTHERIA TOXOID CRM197; DIPHTHERIA VACCINE; DNA VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; OVALBUMIN; PERTUSSIS VACCINE; PLASMID DNA; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE;

ATROPHIC RHINITIS; CHOLERA; DIPHTHERIA; DRUG DELIVERY SYSTEM; EPITHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; INFLUENZA; INFLUENZA VACCINATION; MENINGOCOCCOSIS; NONHUMAN; PERTUSSIS; REVIEW; TETANUS; TUBERCULOSIS; VACCINATION;

EID: 76749100776     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(10)50006-6     Document Type: Review

References (93)

1. Senel S., McClure S.J. - Potential applications of chitosan in veterinary medicine. - Adv. Drug Deliv. Rev., 56 (10), 1467-1480, 2004.
2. Mun S., Decker E.A., Mcclements D.J. - Effect of molecular weight and degree of deacetylation of chitosan on the formation of oil-in-water emulsions stabilized by surfactant-chitosan membranes. - J. Colloid Interface Sci., 296 (2), 581-590, 2006.
3. Schipper N.G., Olsson S., Hoogstraate J.A., deBoer A.G., Varum K.M., Artursson P. - Chitosan as absorption enhancers for poorly absorbable drugs. 2. Mechanism of absorption enhancement. - Pharm. Res., 14, 923-9,1997.
4. Ilium L. - Chitosan and its use as a pharmaceutical excipient.-Pharm. Res., 15, 1326-1331, 1998.
5. Van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H. E. - Chitosan for mucosal vaccination. - Adv. Drug Deliv. Rev., 52, 139-144, 2001.
6. Alpar H.O., Somavarapua S., Atuahb K.N., Bramwell V.W.- Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. - Adv. Drug Deliv. Rev., 57, 411-430, 2005.
7. Moschos S.A., Bramwell V.W., Somaravapu S., Alpar H.O. -Special feature adjuvant synergy: the effects of nasal coadministration of adjuvants. - Immun. Cell Biol., 82, 628-637, 2004.
8. Cui C., Stevens V.C, Schwendeman S.P. - Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. - Vaccine, 25, 500-509, 2007.
9. Zhu B., Qie Y., Wang J., Zhang Y., Wang Q., Xu Y., Wang H. - Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. - Eur. J. Pharm. Biopharm., 66, 318-326, 2007.
10. Borges O., Borchard G., Verhoef J.C., de Sousa A., Junginger H.E. - Preparation of coated nanoparticles for a new mucosal vaccine delivery system. - Int. J. Pharm., 299, 155-166, 2005.
11. Xie Y., Zhou N.J., Gong Y.F., Zhou X.J., Chen J., Hu S.J., Lu N.H., Hou X.H. -The immune response induced by H. pylori vaccine with chitosan as adjuvant and its relation to immune protection. - World J. Gastroenterol., 13, 1547-1553, 2007.
12. Lycke N., Holmgren J. - Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. - Immunology, 59, 301-308, 1986.
13. Matter A. - The effects of Muramyldipeptide (MDP) in cell-mediated immunity. - Cancer Immunology lmmunother., 6, 1432-0851, 1979.
14. Seferian P.G., Martinez M.L. - Immune stimulating activity of two new chitosan containing adjuvant formulations. - Vaccine, 19, 661-668, 2001.
15. Aitken R.J. - Immunocontraceptive vaccines for human use. - J. Reproduct. Immun. 57, 273-287, 2002.
16. McNeela E.A., Jabbal-Gill I., Ilium L., Pizza M., Rappuoli R., Podda A., Lewis D.J.M., Mills K.H.G. - Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.-Vaccine, 22, 909-914, 2004.
17. McNeela E., O'Connan D., Jabbal-Gill I., Ilium L., Davis S.S., Pizza M., Rappuoli R., Mills K.H.G.A. - Mucosally delivered vaccine against diphtheria; formulation of reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic responses following nasal delivery. - Vaccine, 19, 1188-1198, 2000.
18. Van der Lubben I.M., Verhoef J.C, Van Aelst A., Borchard G., Junginger H.E. - Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. - Biomaterials, 22, 687-694, 2001.
19. Van der Lubben I.M., Konings F.A.J., Borchard G., Verhoef J.C., Junginger H.E. - In vivo uptake of chitosan microparticles by murine Peyer's patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. - J. Drug Target., 9, 39-47, 2001.
20. Jabbal-Gill I., Fischer A.N., Rappuoli R., Davis S.S., Illum L. - Stimulation of mucosal and systemic responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. - Vaccine, 16, 2039-2046, 1998.
21. MacLaughlin F.C., Mumper R.J., Wang J., Tagliaferri J.M., Gill I., Hinchcliffe M., Rolland A.P. - Chitosan and depolymerised chitosan oligomers as condensing carriers for in vivo plasmid delivery. - J. Control. Rel., 56, 259-272, 1998.
22. Jiang H.L, Park I.K., Shin N.R., Kangb S.G., Yoo H.S., Kim S.I., Suh S.B., Akaiked T., Cho CS. - In vitro study of the immune stimulating activity of an athrophic rhinitis vaccine associated to chitosan microspheres. - Eur. J. Pharm. Biopharm., 58, 471-476, 2004.
23. Kang M.L., Kang S.G., Jiang H.L., Shin S.W., Lee D.Y., Ahn J.M., Rayamahji N., Park I.K., Shin S.K., Cho C.S., Yoo H.S.-In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT.- Eur. J. Pharm. Biopharm., 63 (2), 215-220, 2006.
24. Nagamoto T., Hattori Y., Takayama K., Maitani Y.-Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. - Pharm. Res., 21, 671-674, 2004.
25. Tengamnuay P., Sahamethapat A., Sailasuta A., Mitra A. - Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts. - Int. J. Pharm., 197, 53-67, 2000.
26. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. - Chitosan solution enhances the immunoadjuvant properties of GM-CSR - Vaccine, 25, 8673-8686, 2007.
27. McClure S.J. - Mucosal delivery of native and recombinant protein vaccines against Trichostrongylus colubriformis. - Int. J. Parasitology, 39 (5), 599-606, 2009.
28. Alarcon J.B., Waine G.W., McManus D.P. - DNA vaccines: technology and application as anti-parasite and anti-microbial agents. - Adv. Parasitai., 42, 343-410, 1999.
29. Kutzler M.A., Weiner D.B. - DNA vaccines: ready for prime time? - Nature Rev., 9, 776-788, 2008.
30. Feigner J.H., Kumar R., Sridhar C.N., Wheeler C.J., Tsai Y.J., Border R., Ramsey P., Martin M., Felgner P.L.- Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. - J. Biol. Chem., 269, 2550-2561, 1994.
31. Gregoriadis G., McCormack B., Obrenovic M., Saffie R., Zadi B., Perrie Y. - Vaccine entrapment in liposomes. - Methods, 19, 156-162, 1999.
32. Illum L., Jabbal-Gill I., Hinchcliffe M., Fischer A.N., Davis S.S. -Chitosan as a novel nasal delivery system for vaccines. - Adv. Drug Deliv. Rev., 51, 81-96, 2001.
33. Atuah K.N., Walter E., Merkle H.P., Alpar H.O. - Encapsulation of plasmid DNA in PLGA-stearylamine microspheres: a comparison of solvent evaporation and spray-drying methods. - J. Microencapsul., 20, 387-399, 2003.
34. Bramwell V.W., Eyles J.E., Somavarapu S., Alpar H.O. - Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen. - Immunology, 106, 412-418, 2002.
35. Somavarapu S., Bramwell V.W., Alpar H.O. - Oral plasmid DNA delivery systems for genetic immunization. - J. Drug Target., 11, 547-553, 2003.
36. Men Y., Audran R., Thomasin C., Eberl G., Demotz S., Merkle H.P., Gander B., Corradin G.-MHCclass I-and class II-restricted processing and presentation of microencapsulated antigens. -Vaccine, 17, 1047-1056, 1999.
37. Kanke M., Morlier E., Geissler R., Powell D., Kaplan A., DeLuca P.P. - Interaction of microspheres with blood constituents. II. Uptake of biodegradable particles by macrophages. - J. Parenter. Sci. Technol., 40 (4), 114-118, 1986.
38. Raychaudhuri S., Rock K.L - Fully mobilizing host defense: building better vaccines. - Nat. BiotechnoL, 16, 1025-1031, 1998.
39. Perrie Y., Frederik P.M., Gregoriadis G. - Liposome-mediated DNA vaccination: the effect of vesicle composition. - Vaccine, 19, 3301-3310, 2001.
40. Alpar H.O, Bramwell V.W. - Current status of DNA vaccines and their route of administration. - Crit. Rev.Ther. Drug Carr. Syst., 19, 307-383, 2002.
41. Yewdell W.J., Norbury C.C., Bennink J.R. - Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumor, transplants, and vaccines. - Adv. Immunol., 73, 1-77, 1999.
42. Roy K., Mao H.-Q., Huang S.-K., Leong K. - Oral gene delivery with chitosan DNA nanoparticles generates immunologic protection in a murine model for peanut allergy. - Nat. Med., 5, 382-390, 1999.
43. Bivas-Benita M.,van Meijgaarden K.E., Franken K.L.M.C, Junginger H.E., Borchard G., Ottenhoff T.H.M., Geluk A.- Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. - Vaccine, 22 (13-14), 1609-1615, 2004.
44. Bivas-Benita M., Laloup M., Versteyhe S., Dewit J., De Braekeleer J., Jongert E., Borchard G. - Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. - Int. J. Pharm., 266, 17-27, 2003.
45. Cui Z., Mumper R.J. - Chitosan-based nanoparticles for topical genetic immunization. - J. Control. ReL, 75 (3), 409-419, 2001.
46. Munier S., Messai I., Delair T., Verrier B., Ataman-OnalY-Cationic PLA nanoparticles for DNA delivery: Comparison of three surface polycations for DNA binding, protection and transfection properties. - Colloid. Surf. B: Biointerfaces, 43 (3-4), 163-173, 2005.
47. Kumar R., Bakowsky U., Lehr C.M. - Preparation and characterization of cationic PLGA nanospheres as DNA carriers. - Biomaterials, 25, 1771-1777, 2004.
48. Davies O.R., Head L., Armitage D., Pearson E.A., Davies M.C., Marlow M., Stolnik S. - Surface modification of microspheres with steric stabilizing and cationic polymers for gene delivery. - Langmuir, 24, 7138-7146, 2008.
49. Fischer S., Foerg C., Ellenberger S., Merkle H.P., Gander B. - One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands. - J. Control. Rel., 111, 135-144, 2006.
50. Jaganathan K.S., Vyas S. P. - Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. - Vaccine, 24, 4201-4211, 2006.
51. Zhou X., Liu B., Yu X., Zha X., Zhang X., Chen Y., Wang X., Jin Y., Wu Y., Chen Y., Shan Y., Chen Y., Liu J. Kong W., Shen J. - Controlled release of PEI/DNA complexes from mannosebearing chitosan microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine. - J. Control. Rel., 121, 200-207, 2007.
52. Gombotz W.R., Wee S.F. - Protein release from alginate matrices. - Adv. Drug Deliv. Rev., 31, 267-285, 1998.
53. Chretien C., Chaumeil J.C. - Release of a macromolecular drug from alginate-impregnated particles.- Int. J. Pharm., 304, 18-28, 2005.
54. Douglas K.L., Tabrizian M. - New approach to the preparation of alginate-chitosan nanoparticles as gene carriers. - J. Biomater. Sci. Polymer Edn., 16, 43-56, 2005.
55. Ciofani G., Raffa V., Menciassi A. Dario P.- Alginate and chitosan particles as drug delivery system for cell therapy. - Biomed. Microdevices, 10, 131-140, 2008.
56. Borges O., Cordeiro-da-Silva A., Romeijn S.G., Amidi M., de Sousa A., Borchard G., Junginger H.E. - Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. - J. Control. Rel., 114, 348-358, 2006.
57. Tokura S., Tamura H., Azuma I.- Immunological aspects of chitin and chitin derivatives administered to animals. - Experientia, 87, 279-292, 1999.
58. Illum L. - Bioadhesive formulations for nasal peptide delivery. - In: Mathiowitz E., Lehr C.M., Chickering D.S. (Eds.), Bioadhesion in Drug Delivery, Issues in Fundamental, Novel Approaches and Development, Marcel Dekker, New York, 1998, pp. 507-539.
59. Hall G., Lund L., Lamb J.R., Jarman E.R. - Kinetics and mode of peptide delivery via the respiratory mucosa determine the outcome of activation versus TH2 immunity in allergic inflammation of the airways. - J. Allergy Clin. Immunol., 110, 883-890, 2002.
60. Murthy G.N., Xu M., Prechet J.M. - Cross-linked microparticles as carriers for the delivery of plasmid DNA for vaccine development. - Bioconjug. Chem., 15, 467-474, 2004.
61. Behrens I., Pena A.I.V., Alonso M.J., Kissel T. - Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport.- Pharm. Res., 19, 1185-1193, 2002.
62. Mills K.H.G., Cosgrove C., McNeela E.A., Sexton A., Giemza R., Jabbal-Gill I., Church A., Lin W., Illum L., Podda A., Rappuoli R., Pizza M., Griffin G.E., Lewis D.J.M.- Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A. - Infect. Immun., 71 (2), 726-732, 2003.
63. Huo Z., Sinha R., McNeela E.A., Borrow R., Giemza R., Cosgrove C., Heath P.T., Mills K.H.G., Rappuoli R., Griffin G.E., Lewis D.J.M. - Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitides serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. - Infect. Immun., 73 (12), 8256-8265, 2005.
64. Read R.C., Naylor S.C., Potter CW., Bond J., Jabbal-Gill L, Pisher A., Illum L., Jennings R. - Effective nasal influenza vaccine delivery using chitosan.- Vaccine, 23 (35), 4367-4374, 2005.
65. Strand S.P., Tømmeraas K., Varum K.M., Østgaard K. - Electrophoretic light scattering studies of chitosans with different degrees of N-acetylation. - Biomacromolecules, 2, 1310-1314, 2001.
66. Area H.C., Günbeyaz M., Senel S - Chitosan-based systems for the delivery of vaccine antigens. - Expert Rev. Vaccines, 8, 937-953, 2009.
67. Sahni J.K., Chopra S., Ahmad F.J., Khar R.K.- Potential prospects of chitosan derivative trimethyl chitosan chloride (TMC) as a polymeric absorption enhancer: synthesis, characterization and applications. - J. Pharm. Pharmacol., 60, 1111-1119, 2008.
68. Polnok A., Borchard G., Verhoef J.C., Sarisuta N., Junginger H.E. - Influence of methylation process on the degree of quaternization of N-trimethyl chitosan chloride. - Eur. J. Pharm. Biopharm., 57, 77-83, 2004.
69. Hamman J.H., Schultz C.M., Kotzé A.F. - N-trimethyl chitosan Chloride: optimum degree of quaternization for drug absorption enhancement across epithelial cells. - Drug. Dev. Ind. Pharm., 29, 161-172, 2003.
70. Kean T., Roth S.Thanou M. -Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. - J. Control. Rel., 103, 643-53, 2005.
71. Jintapattanakit A., MaoS., Kissel T., JunyaprasertV.B.- Physicochemical properties and biocompatibility of N-trimethyl chitosan: effect of quaternization and dimethylation. - Eur. J. Pharm. Biopharm., 70, 563-571, 2008.
72. Verheul R.J., Amidi M., van der Wal S., van Riet E., Jiskoot W., Hennink W.E. - Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan. - Biomaterials, 29, 3642-3649, 2008.
73. Boonyo W., Junginger H.E., Waranuch N., Polnok A., Pitaksuteepong T. - Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. - J. Control. Rel., 121, 168-75, 2007.
74. Baudner C.B., Morandi M., Giuliani M.M., Verhoef J.C., Junginger H.E., Costantino P., Rappuoli R., Giudice G.D. - Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. - J. Infect. Dis., 189, 828-832, 2004.
75. Hagenaars N., Mastrobattista E., Verheul R.J., Mooren I., Glansbeek H.L., Heldens J.G., van den Bosch H., Jiskoot W. - Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration. - Pharm. Res., 26, 1353-1364, 2009.
76. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., Illum L. - Evaluation of the clearance characteristics of bioadhesive systems in humans. - Int. J. Pharm., 178, 55-65, 1999.
77. Soane R.J., Hinchcliffe M., Davis S.S., Illum L. - Clearance characteristics of chitosan based formulations in the sheep nasal cavity. - Int. J. Pharm., 217, 183-191, 2001.
78. Baudner B., Verhoef J.C., Giuliani M.M., Peppoloni S., Rappuoli R., DelGiudice G., Junginger H.E. - Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. - J. Drug Target., 13, 489-498, 2005.
79. Amidi M. ,Romeijn S.G., Verhoef J.C., Junginger H.E., Bungener L., Huckriede A., Crommelin D.J., Jiskoot W.-N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. - Vaccine, 25, 144-153, 2007.
80. Sayin B., Somavarapu S., Li X.W., Thanou M., Sesardic D., Alpar H.O., Senel S. - Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. - Int. J. Pharm., 363, 139-148, 2008.
81. Amidi M., Pellikaan H.C., Hirschberg H., de Boer A.H., Crommelin D.J., Hennink W.E., Kersten G., Jiskoot W. - Diphtheria toxoidcontaining microparticulate powder formulations for pulmonary vaccinatiopn: preparation, charactrization and evaluation in guinea pigs. - Vaccine, 25, 6818-6829, 2007.
82. Van der Lubben I.M., Verhoef J.C., Fretz M.M., van Opdorp F.A.C., Mesu I., Kersten G.-Trimethyl chitosan chloride (TMC) as novel excipient for oral and nasal immunization against diphtheria. - STP Pharm. Sci., 12, 235-242, 2002.
83. Chen F., Zhang Z.R., Yuan F., Qin X., Wang M., Huang Y - In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. - Int. J. Pharm., 349, 226-233, 2008.
84. Slütter B., Plapied L., Fievez V., Alonso S.M., des Rieux A. Schneider Y.J., van Riet E., Jiskoot W., Préat V. - Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. - J. Control. Release., doi: 10.1016./j. jconrel.2009.05.011, 2009.
85. Jiang L., Qian F., He X., Wang F, Ren D., He Y., Li K., Sun S., Yin C. - Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice. - J. Gene Med., 9, 253-264, 2007.
86. Sayin B., Sayin B., Somavarapu S., Li X.W., Sesardic D., Senel S., Alpar O.H. - TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. - Eur. J. Pharm. Sci., 2009, doi:10.1016/j.ejps.2009.08.010.
87. Jiang H.L., Kang M.L, Quan J.S., Kang S.G., Akaike T., Yoo H.S., Cho C.S. -The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. - Biomaterials, 29, 1931-1939, 2008.
88. Heuking S., Iannitelli A., Di Stefano A., Borchard G. - Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination. - Int. J. Pharm., 381, 97-105, 2009.
89. O'Hagan D.T., Singh M., Ulmer J.B. - Microparticle-based technology for vaccines. - Methods, 40, 10-19, 2006.
90. Heuking S., Adam-Malpel S., Sublet E., Iannitelli A., di Stefano A., Borchard G. - Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. - J. Drug Target., 17, 662-670, 2009.
91. www.clinicaltrials.gov/ct2/show/NCT00806962?term=ligocyte &rank=1
92. Lai W.F., Lin M.C. - Nucleic acid delivery with chitosan and its derivatives. - J. Control. Rel., 134, 158-168, 2009.
93. Germershaus O., Mao S., Sitterberg J., Bakowsky U., Kissel T. - Gene delivery using chitosan, trimethyl chitosan or polyethylenglycol-graft-trimethyl chitosan block copolymers: establishment of structure-activity relationships in vitro. - J. Control. Rel., 125, 145-154, 2008.